Cobenfy(KarXT)如何用药

Patients should understand the medication method of Cobenfy (KarXT), applicable groups and contraindications that must be strictly avoided under the professional guidance of doctors.

How to use Cobenfy (KarXT)

1. Dose escalation scheme (titrated administration)

(1). Starting dose: 50mg/20mg (xanomeline/trospium chloride), taken orally, twice a day for at least 2 days.

(2) First increase: increase to 100mg/20mg, orally, twice a day for at least 5 days.

(3) Target dose: According to the patient's tolerance and treatment response, it can be further increased to 125mg/30mg, orally, twice a day.

(4). Maximum dose: 125mg/30mg, twice a day is the maximum recommended dose.

2. Key dosing timing

(1) Take on an empty stomach: To ensure drug absorption, it should be taken at least 1 hour before a meal or at least 2 hours after a meal.

(2) Swallow the whole capsule: Do not open, chew or crush the capsule. Take the whole capsule with warm water.

3. Dose adjustment for special groups

Elderly patients: The recommended starting dose is 50mg/20mg twice daily, the maximum dose should not exceed 100mg/20mg twice daily, and a slower dose escalation rate should be adopted.

The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Applicable groups of Cobenfy (KarXT)

1. Core indications

Cobenfy is clearly approved for the treatment of schizophrenia in adults.

2. Instructions for use by special groups

(1) Children and adolescents: Safety and effectiveness have not been established, and it is not suitable for people under the age of 18.

(2) Elderly people (≥65 years old): Can be used, but need to start with a low dose and closely monitor adverse reactions such as urinary retention.

(3) Patients with liver and kidney dysfunction:

Mild renal dysfunction: conventional dosage can be used.

Moderate to severe renal insufficiency: Not recommended.

Mild hepatic insufficiency: Not recommended.

Moderate to severe hepatic insufficiency: Use prohibited.

(4) Pregnant and lactating women: There is currently a lack of human data, and doctors should decide whether to use it after weighing the pros and cons.

Contraindications for Cobenfy (KarXT)

The following patients are absolutely prohibited from using Cobenfy, otherwise it may lead to serious or even life-threatening consequences:

1. Patients with urinary retention: Cobenfy may aggravate the condition and cause the inability to urinate.

2. Patients with moderate to severe liver dysfunction: refers to patients with Child-Pugh classification B or C. After use, the blood concentration of the drug will significantly increase, significantly increasing the risk of adverse reactions.

3. Patients with gastric retention: Drugs will slow down gastrointestinal motility and aggravate delayed gastric emptying.

4. Patients allergic to ingredients: patients with a history of allergy to Cobenfy, Xanomeline, Trospium Chloride or any of the excipients.

5. Patients with untreated narrow-angle glaucoma: The anticholinergic effect of the drug may induce acute glaucoma attacks.